Absorcol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Absorcol

Property Description
Active ingredient Ezetimibe
Form Tablet (Oral)
Pharmacological class Selective Cholesterol Absorption Inhibitor
Common use Management of Hypercholesterolemia and Dyslipidemia
Origin Synthetic Compound (Azetidinone class)
Prescription Status Prescription-Only Medicine (Rx)

What Type of Medicine is Absorcol (Ezetimibe)?

Absorcol is a prescription-only medication classified as a selective cholesterol absorption inhibitor, meaning it is used to manage high blood lipid levels to address conditions like hypercholesterolemia and dyslipidemia. The core active ingredient is Ezetimibe, a synthetic compound that belongs to the azetidinone chemical class. Ezetimibe is used as a monotherapy or combination therapy for primary hypercholesterolemia to help lower elevated cholesterol levels.

A differentiating feature of Ezetimibe is that it is often utilized as an add-on therapy when statins alone are insufficient, or as an alternative for patients who may not tolerate higher statin doses. It is available as a monotherapy product in tablet form for oral administration, offering flexibility for tailoring a patient's lipid-lowering regimen.


General Purpose: Targeted Intestinal Blocking

Absorcol's general purpose is to directly interfere with the body's uptake of cholesterol from the digestive tract, thereby assisting in lowering its circulating levels in the blood. The drug achieves this by precisely targeting and blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein, a key transporter found in the wall of the small intestine. The primary mechanism of Ezetimibe is inhibiting the intestinal absorption of both dietary and biliary cholesterol. By reducing intestinal cholesterol absorption, Absorcol decreases the total cholesterol load delivered to the liver, which supports the overall goal of achieving and maintaining targeted lipid levels.

What side effects are possible with Absorcol?

Possible side effects and safety information

The safety profile for Absorcol (Ezetimibe) is officially documented based on clinical trials and post-marketing reports, classifying potential effects by frequency and the body system involved.

Frequency-Classified Adverse Reactions

Adverse reactions that appeared commonly in clinical trials, at an incidence of 2% or greater than placebo, primarily affect the musculoskeletal and gastrointestinal systems, and are grouped as Common in regulatory labeling. These include upper respiratory tract infection, diarrhea, arthralgia (joint pain), sinusitis, and pain in extremity [FDA Label]. When used in combination with a statin, additional common effects may include myalgia (muscle pain) and back pain.

Serious Adverse Reactions and Safety Constraints

The official prescribing information highlights potential serious adverse reactions related to skeletal muscle and liver function. These include the risk of myopathy and rhabdomyolysis (severe muscle breakdown), a risk documented to increase when Ezetimibe is used alongside a statin or fibrate [EMA SmPC]. Hepatitis and sustained elevations in liver enzymes (transaminases) have also been reported in the post-marketing setting.

Monitoring of liver enzymes is included as a safety note in the regulatory documents, and the use of Absorcol is not recommended in patients who have moderate or severe hepatic insufficiency [FDA Label]. The medicine is contraindicated in individuals with a known hypersensitivity to Ezetimibe or any component of the formulation.

Overdose and Emergency Response

Overdose and when to seek help for Absorcol (Ezetimibe)

This information reflects the documented findings and required actions outlined in official government regulatory documents.

Overdose Profile Summary

Element Official Regulatory Statement
Documented Presentations No specific clinical signs or symptoms were consistently documented following single oral doses of ezetimibe up to 50 mg/day for 14 days or up to 120 mg/day for 28 days in clinical trials. The drug was reported as generally well tolerated.
Antidote Availability No specific antidote is known for ezetimibe overdosage.
Required Management Treatment for overdosage must be symptomatic and supportive.

Emergency Action Guidance

In the event of a suspected Absorcol overdosage, it is officially required to seek immediate medical attention. Due to the absence of specific documented toxicity symptoms, management focuses on supportive care.

  • Individuals must contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for specific patient management advice.
  • The official regulatory guidance emphasizes that treatment should be symptomatic and supportive, addressing any signs or discomfort that may occur.

Regulatory Context

The regulatory profile for Absorcol overdose is defined by the absence of specific documented symptoms in trials. This documented finding underpins the mandated management protocol: supportive care and immediate consultation with specialized toxicology services. The official statements confirm that no specific reversal agent or antidote exists.

Therapeutic Uses of Absorcol

What Absorcol Treats: Main Uses and Benefits

Absorcol is a therapeutic option utilized to assist in the symptomatic management of a variety of acute and chronic conditions. It is commonly used to support relief from symptoms associated with seasonal allergies and mild skin irritation. The medication may help to reduce general discomfort and supports temporary functional improvement during these acute episodes.

For individuals managing long-term conditions, Absorcol contributes to managing the frequency and severity of associated symptoms, potentially aiding in better daily well-being. This includes providing supportive care for symptoms such as itching, minor swelling, or congestion.

Quick Fact: Relief for Itching and Minor Swelling

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Absorcol (ezetimibe) eligibility is strictly defined by government regulatory documents, focusing on age, organ function, and concurrent medication use.

Contraindicated Populations

Use is contraindicated in patients with a known hypersensitivity to ezetimibe or any component. When used in combination with a statin, Absorcol is also contraindicated in pregnant or nursing women, and in patients with active liver disease or unexplained persistent elevations in liver enzymes, as these are absolute contraindications for the statin component.

Age- and Condition-Based Eligibility

Population Status Regulatory Classification
Adults Generally approved for use.
Children Approved for specific conditions (e.g., Heterozygous Familial Hypercholesterolemia) in those ge 10 years of age; use is not established in children under 6.
Hepatic Impairment Not recommended in moderate or severe impairment due to increased drug exposure.
Renal Impairment No dosage adjustment is required for monotherapy, even in severe renal disease.

Eligibility-related restrictions include that co-administration with fibrates other than fenofibrate is generally not recommended. Absorcol monotherapy should be used during pregnancy only if clearly necessary, and is not recommended during lactation.

What should I know about interactions with other medicines?

Absorcol Interactions with Other Medicines and Products

The interaction profile for Absorcol (Ezetimibe) is defined by its effects on systemic exposure and specific co-administration risks documented in regulatory labels. The official prescribing information notes that the medicine is unlikely to affect the metabolism of many drugs, as it is neither an inhibitor nor an inducer of the major Cytochrome P450 enzyme system.

Interacting Substance/Class Official Interaction Outcome Regulatory Constraint
Immunosuppressants (e.g., Cyclosporine) Significant uparrow AUC of Absorcol (via OATP transporter inhibition). Exposure monitoring for the co-administered drug is required.
Fibrates (e.g., Gemfibrozil) Increased Absorcol AUC and a documented additive risk of cholelithiasis. Use with caution due to documented safety risk.
Bile Acid Sequestrants (e.g., Cholestyramine) Significant downarrow Exposure of Absorcol (sim 55% AUC) due to absorption interference. Must be separated by 2 hours before or 4 hours after Absorcol.
Coumarin Anticoagulants (e.g., Warfarin) Post-marketing reports indicate a potential for increased International Normalized Ratio (INR). INR monitoring is required upon initiation or adjustment of Absorcol.

Regulatory constraints specify that co-administration with statins or fibrates is formally restricted in patients with active liver disease or unexplained persistent elevations in serum transaminases. The official label also notes a 4- to 6-fold increase in Absorcol exposure in patients with moderate to severe hepatic impairment, resulting in a regulatory non-recommendation for use in this specific population.

Mechanism of Action

Selective Blockade of Intestinal Cholesterol Uptake

Absorcol (Ezetimibe) works by the direct, selective inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) protein, a key sterol transporter located on the intestinal wall. This action prevents the uptake of both dietary and biliary cholesterol from the digestive tract into the bloodstream, significantly reducing the cholesterol load delivered to the liver.


Indirect Modulation of Hepatic Clearance

The resulting reduction in cholesterol delivery to the liver triggers a physiological feedback response that modulates hepatic cholesterol homeostasis. The liver compensates for the reduced supply by up-regulating the expression and function of Low-Density Lipoprotein (LDL) receptors on its cell surface. This enhanced receptor activity increases the liver’s capacity to actively capture and remove LDL-C from the systemic circulation.


Complementary Action in Dual Therapy

When used alongside a statin, Absorcol enables a complementary dual mechanism targeting cholesterol absorption (exogenous source) and synthesis (endogenous source). This combined, additive effect overcomes the body's tendency toward increased intestinal absorption when synthesis is inhibited, resulting in a greater modification of circulating cholesterol levels.

Dosage and Administration Information

Instruction Map: How to use Absorcol — Administration Guidelines

This map formalizes the high-level administration protocol for Absorcol (Ezetimibe).


Administration Scope

Feature Description
Route of administration The medicine is designated for oral administration only.
Dosing schedule The standard dose is a 10 mg tablet taken once daily. This consistent dose applies to both adults and pediatric patients aged 9 or 10 years and older, depending on the specific condition.
Timing in relation to meals (if applicable) The tablet may be administered with or without food.
Age-group administration rules No dosage adjustment is required for older adults or patients with renal impairment. The use of Ezetimibe is not recommended in patients who have moderate or severe hepatic impairment.
Missed-dose rules If a scheduled dose is missed, it should be taken as soon as it is remembered. Patients are instructed not to double the next dose to compensate for the missed one.
Special procedural conditions When co-administered with a bile acid sequestrant (another type of lipid-lowering therapy), Absorcol must be taken at least 2 hours before or 4 hours after the sequestrant dose.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Oral
Frequency pattern Daily (once a day)
Use-context constraints Mandatory timing separation from bile acid sequestrants.

Resulting Procedural Structure

Step sequence:

  • Intake: Take the 10 mg tablet orally, once daily.
  • Flexibility: Administration is flexible regarding meal times.
  • Co-Therapy Rule: If taking a bile acid sequestrant, observe the mandatory 2-hour before / 4-hour after timing rule.

Connection to the overall use protocol (2–4 sentences): The administration protocol is built around a fixed 10 mg, once-daily oral dose that requires minimal preparation, establishing a simple usage pattern for long-term therapy. The key procedural instruction is the required timing adjustment when combining this medicine with certain other cholesterol-modifying agents to maintain proper absorption. The dose is designed to be consistent across most patient populations.

Recent Clinical Evidence

The research for Absorcol (Ezetimibe) has been extensively studied for its role in addressing high levels of cholesterol and other lipids in the blood. Research exploring this role has included numerous Randomized Controlled Trials (RCTs) and comprehensive reviews, which were used to construct the evidence base. These studies explored the medicine's role alone or when added to other existing treatments, such as statins, in adults managing primary hypercholesterolemia or mixed dyslipidemia.


Focusing on Biomarker Measurements

Studies monitored certain lipid biomarkers in the blood, which are used as surrogate endpoints. Research examined how measurements like LDL cholesterol and triglycerides evolved in the observed populations. Findings describe patterns related to shifts in these biomarker levels when Ezetimibe was used. Findings from studies that solely tracked biomarker changes, however, offer limited insight into long-term clinical outcomes.


Focusing on Cardiovascular Outcomes

To explore the relationship with patient health over time, large-scale, long-term cardiovascular outcome trials have been conducted, monitoring clinical events over periods that often spanned four to seven years. Research examined outcomes related to Major Atherosclerotic Cardiovascular Events (MACE), such as heart attack and stroke. These long-term studies provide context about patterns between cholesterol levels and the occurrence of these major events in the study groups.


Evidence in Specific Patient Populations

Research has explored the role of Absorcol in various patient groups, including older adults (aged 75 and over) and individuals managing certain conditions like Chronic Kidney Disease (CKD). Studies also evaluated children and adolescents with inherited high cholesterol conditions. Data for certain groups remain insufficient when compared to the large volume of evidence available for the core adult population.


Understanding Research Gaps and Uncertainty

Despite the significant volume of research, certain areas of uncertainty exist. For example, evidence exploring the long-term clinical outcomes of Absorcol when used as monotherapy (without a statin) is limited, as the majority of definitive research examined its use as an add-on treatment. Furthermore, initial studies provided mixed findings and did not report consistent observations in some areas. This confirms that certainty remains low for questions not directly addressed by the largest trials.

Frequently Asked Questions (FAQ)

Common questions about Absorcol (FAQ)


Q: What is the main difference between Absorcol and other similar treatments?

Official information states that Absorcol's mechanism is different from statin drugs. Absorcol selectively blocks the absorption of cholesterol in the small intestine, while statins primarily work by reducing the body's own cholesterol production. This unique action is often used in combination with statins for a comprehensive approach to lowering cholesterol.


Q: Does Absorcol interact with common pain relievers like ibuprofen?

The official product information for Absorcol does not list common non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, as specific interaction risks. Since the drug is not metabolized by the major enzyme system (Cytochrome P450) that breaks down many other medicines, it is generally not predicted to interact with many drugs.


Q: Can Absorcol be used to prevent a specific condition?

Studies indicate that when Absorcol is added to statin therapy, the combination can reduce the risk of Major Atherosclerotic Cardiovascular Events (MACE) in patients who have recently had a heart event. This reduction in risk includes events such as heart attack and stroke. Absorcol's use is often focused on managing lipid levels to address these risks.


Q: What does 'contraindicated' mean in relation to Absorcol?

In regulatory content, 'contraindicated' means there is a known reason or condition that makes using the drug formally not allowed due to safety risks. For Absorcol, this applies to known hypersensitivity (severe allergy) to the drug. When used with a statin, the combination is also contraindicated in pregnant or nursing women, and in those with active liver disease.


Q: Do studies suggest Absorcol is generally well tolerated?

Regulatory reports from clinical trials generally describe Absorcol as well-tolerated. The documented adverse reactions were typically mild to moderate in severity and occurred at similar rates to placebo. Common effects include joint pain, diarrhea, and upper respiratory tract infection.


Q: Can women who are planning pregnancy take Absorcol?

Official patient information advises women to consult with a healthcare professional if they are planning pregnancy. The medication is only recommended during pregnancy if clearly necessary. If Absorcol is taken alongside a statin, that combination is strictly contraindicated (not allowed) during pregnancy or for women who may become pregnant.


Q: How does Absorcol affect the absorption of nutrients?

Absorcol's action is selective, meaning it primarily focuses on blocking the absorption of cholesterol. Official documents confirm that the medicine does not significantly affect the body's absorption of other important non-cholesterol nutrients, such as fat-soluble vitamins or triglycerides.


Q: Why do official documents list so many potential drug interactions for Absorcol?

Official regulatory documents list drug interactions because they have been shown to either significantly increase the drug's safety risks or reduce its effectiveness. This is often related to the drug's specific absorption or elimination pathways rather than general metabolism. Examples include interference by bile acid sequestrants and effects on certain transport proteins.


Q: Why is the drug intended for continuous use?

Absorcol is prescribed for the long-term management of chronic conditions like high cholesterol. Studies have shown that when the medication is stopped, the body’s cholesterol levels tend to return to their original elevated state. For this reason, continuous use may be required to maintain the desired lipid-lowering results.


Q: What is the risk of an allergic reaction to Absorcol?

Absorcol is contraindicated in individuals with a known hypersensitivity (allergy) to the drug, as allergic reactions have been reported. Though rare, serious allergic reactions, including anaphylaxis and severe swelling (angioedema), have occurred in the post-marketing setting.


Q: How quickly does Absorcol start to work?

The active form of Absorcol typically reaches its highest level in the bloodstream within one to two hours after taking a single dose. Therapy focuses on modifying lipid levels over the long term, and these changes are typically monitored by a healthcare professional during follow-up visits.


Q: Does Absorcol cause weight gain?

Official safety summaries from clinical trials do not list weight gain as a common adverse reaction. In fact, some studies noted a weight decrease as an uncommon effect, but weight changes are generally not a primary safety focus of the drug's profile.


Q: Can Absorcol affect my energy levels?

Official safety reports list fatigue (tiredness) as a common adverse reaction for Absorcol monotherapy. Other related effects such as unusual weakness (asthenia) have also been reported in clinical trial settings.


Q: Are there any foods or drinks that interact with Absorcol?

Official regulatory documents state that Absorcol can be taken with or without food, giving patients flexibility with their dosing time. The medicine's effectiveness is not affected by general food intake.


Q: Is there a generic version of Absorcol available?

Yes, the drug is available under its active ingredient name, ezetimibe. This generic form is bioequivalent to the brand name product, meaning it works the same way and provides the same benefit.


Q: Is it safe to drink alcohol while taking Absorcol?

In general, regulatory documents do not include a specific restriction on drinking alcohol while taking Absorcol as monotherapy. However, if Absorcol is taken in combination with a statin, the consumption of substantial quantities of alcohol may increase the potential for liver-related side effects.


Q: What happens when you stop taking Absorcol?

If the medication is stopped, studies indicate that the cholesterol-lowering effects will reverse, causing lipid levels to rise again. Official patient information advises against discontinuing Absorcol without discussing it first with a healthcare professional.


Q: Is it true that Absorcol is sometimes used for conditions not listed in the main uses?

Official regulatory documents only cover the approved indications (uses) for Absorcol. If the medicine is prescribed for a condition not listed in the main documentation, official patient information advises referring to the prescribing doctor or pharmacist for details.


Q: Can a person who is lactose intolerant take Absorcol?

The tablet formulation of Absorcol contains lactose monohydrate as an inactive ingredient. Patients with known inherited conditions related to sugar malabsorption or intolerance are advised to consult with a healthcare professional to confirm if the formulation is appropriate for them.


Q: How is Absorcol eliminated from the body?

Official pharmacokinetics information states that the drug and its active form are eliminated from the body through two main pathways. These are biliary excretion (via bile/feces) and renal excretion (via the kidneys/urine).


Q: What are the official guidelines regarding driving while on Absorcol?

Regulatory documents indicate that certain side effects, such as dizziness or fatigue, have been reported that may affect the ability to drive or operate machinery. Patients are advised to use caution and monitor their own response to the drug before engaging in these activities.


Q: Is Absorcol a Schedule V controlled substance?

Absorcol (ezetimibe) is designated as a Prescription Only Medicine (Rx). It is not classified as a controlled substance under the US Controlled Substances Act.

How should Absorcol be stored and disposed of?

Official Storage and Disposal Requirements

Absorcol (ezetimibe) tablets must be stored according to strict regulatory conditions to maintain their stability.

Storage Conditions

The medicine requires storage at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be kept from freezing and stored away from heat, moisture, and direct light.

Handling and Safety

Tablets must be kept in a closed container and stored out of the sight and reach of children to comply with mandated child-safety requirements. Outdated or no longer needed medicine should not be kept.

Disposal Instructions

Official disposal instructions advise that the medicine must not be thrown away via wastewater or household trash. Patients must consult a healthcare professional regarding the proper method for discarding unused or expired Absorcol.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Absorcol found in:

A-Z Index: